Lifeline offered for patients with dangerous Tumor-Caused blood sugar crashes
NCT ID NCT07262970
Summary
This program provides early access to an investigational drug called ersodetug for people with severe, uncontrolled low blood sugar caused by insulin-producing tumors. It is for patients who cannot participate in the main clinical trials and whose current treatments are not working. The goal is to help control dangerous blood sugar drops when standard options have failed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR-ASSOCIATED HYPERINSULINISM (TUMOR HI) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.